| Pharmaceutical Information |
| Drug Name |
Binimetinib |
| Drug ID |
BADD_D02535 |
| Description |
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib] [A34275,L3335].
On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.[L3335] |
| Indications and Usage |
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EE03 |
| DrugBank ID |
DB11967
|
| KEGG ID |
D10604
|
| MeSH ID |
C581313
|
| PubChem ID |
10288191
|
| TTD Drug ID |
D0C4LF
|
| NDC Product Code |
70255-010; 54893-0119 |
| UNII |
181R97MR71
|
| Synonyms |
binimetinib | Mektovi | MEK162 |
|
| Chemical Information |
| Molecular Formula |
C17H15BrF2N4O3 |
| CAS Registry Number |
606143-89-9 |
| SMILES |
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
